一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (397k)
Article in Japanese

Case Report

Successful alectinib rechallenge after drug-induced lung injury: a case report of Hanabiratake-induced interstitial lung injury

Fujihiro Kurea,b  Yu Satoa,c  Kengo Murataa  Miyako Kitazonoa  Akihiko Wadaa  Mikio Takamoria 

aDepartment of Respiratory Medicine and Medical Oncology, Tokyo Metropolitan Tama Medical Center
bDepartment of Respiratory Medicine, Funabashi Municipal Medical Center
cDepartment of Emergency and General Medicine, Tokyo Metropolitan Tama Medical Center

ABSTRACT

An 81-year-old male patient who received alectinib, a tyrosine kinase inhibitor (TKI), for lung adenocarcinoma developed lung injury. He was also taking Hanabiratake (Sparassis crispa), a type of edible fungus, as a dietary supplement. After all medicines and supplements including alectinib and Hanabiratake were stopped and corticosteroid was administered, the lung injury improved. A drug-induced lymphocyte stimulation test (DLST) was positive only for Hanabiratake, and the lung injury did not recur after resumption of alectinib administration. Based on these findings, drug-induced lung injury caused by Hanabiratake was diagnosed. Even when lung injury arises during treatment such as TKI therapy which often causes lung injury, it is still important to investigate possible causative agents including other medicines and supplements.

KEYWORDS

Drug-induced lung injury  Sparassis crispa  Alectinib  Drug-induced lymphocyte stimulation test (DLST) 

Received 25 Nov 2021 / Accepted 1 Mar 2023

AJRS, 12(3): 144-148, 2023

Google Scholar